Gurgaon Samachar

Adrenocortical Carcinoma Epidemiology Forecast to 2030

 Breaking News
  • No posts were found

Adrenocortical Carcinoma Epidemiology Forecast to 2030

April 22
01:51 2020
Adrenocortical Carcinoma Epidemiology Forecast to 2030

Delveinsight Business Research
DelveInsight’s ‘Adrenocortical Carcinoma Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Adrenocortical Carcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

According to the National Cancer Institute, Adrenocortical Carcinoma (ACC) is a rare cancer that originates in the outer layer of the adrenal gland. ACC is also called cancer of the adrenal cortex. A tumor of the adrenal cortex may be functioning (produces surplus hormones than usual) or nonfunctioning (does not produce surplus hormones than usual). Most adrenocortical tumors are functioning. 

The hormones made by functioning tumors may cause sure signs or symptoms of the disease; the common symptoms caused by ACC include a lump in the abdomen, pain in the abdomen or back, and feeling of fullness in the abdomen. 

A non functioning adrenocortical tumor may not cause signs or symptoms in the early stages. The excessive hormones produced by a functioning tumor include cortisol, aldosterone, testosterone, and estrogen. These excessive hormones cause specific symptoms.

The DelveInsight Adrenocortical Carcinoma epidemiology report gives a thorough understanding of the Adrenocortical Carcinoma by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. 

It also provides treatment algorithms and treatment guidelines for Adrenocortical Carcinoma in the US, Europe, and Japan. The report covers the detailed information of the Adrenocortical Carcinoma epidemiology scenario in seven major countries (US, EU5, and Japan).

 

Key Highlights Of The Report

  • According to the study by Johanssen et al. titled “Deficits in the Management of Patients With Adrenocortical Carcinoma in Germany,” the incidence of ACC is one per million population.  and females are more frequently affected than males, with a female:male ratio of 1.5 : 1.

  • ACC is a rare malignancy with poor prognosis. It occurs at any age, with two peak incidences: the first in the first decade and the second between 40‒50 years.

  • The study conducted by Sharma et al. titled “The Characteristics and Trends in Adrenocortical Carcinoma: A United States Population-Based Study,” shows that the median age at diagnosis was 55 years.

  • According to the study by Wang et al. titled “Prognostic Factors of Adrenocortical Carcinoma: An Analysis of the Surveillance Epidemiology and End Results (SEER) Database,” ACC was predominant in females (60.6%) than in males (39.4%).

Adrenocortical Carcinoma Epidemiology Forecast

Request for Sample Pages: 

https://www.delveinsight.com/sample-request/adrenocortical-carcinoma-epidemiology-forecast

 

Adrenocortical Carcinoma Epidemiology

Delveinsight’s Adrenocortical Carcinoma epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries. 

The Adrenocortical Carcinoma epidemiology data are studied through all possible divisions to give a better understanding of the Disease scenario in 7MM. 

The Adrenocortical Carcinoma epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. 

It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

 

Scope of the Report

  • The report provides insight into the historical and forecasted patient pool of Adrenocortical Carcinoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.

  • The report assesses the disease risk and burden and highlights the unmet needs of Adrenocortical Carcinoma.

  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.

  • The Adrenocortical Carcinoma report provides a detailed overview explaining Adrenocortical Carcinoma causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.

  • The Adrenocortical Carcinoma Epidemiology Report and Model provide an overview of the risk factors and global trends of Adrenocortical Carcinoma in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan).

  • The report provides the segmentation of the Adrenocortical Carcinoma epidemiology. 

 

Key Questions Covered In The Adrenocortical Carcinoma Report Include:

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Adrenocortical Carcinoma?

  • What are the key findings pertaining to the Adrenocortical Carcinoma epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?

  • What would be the total number of patients of Adrenocortical Carcinoma across the 7MM during the forecast period (2017-2030)?

  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?

  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?

  • What is the disease risk, burden and unmet needs of the Adrenocortical Carcinoma?

  • What are the currently available treatments of Adrenocortical Carcinoma?

 

Key Benefit of Adrenocortical Carcinoma Epidemiology Report 

  • The Adrenocortical Carcinoma Epidemiology report will allow the user to –

  • Develop business strategies by understanding the trends shaping and driving the global Adrenocortical Carcinoma market

  • Quantify patient populations in the global Adrenocortical Carcinoma market to improve product design, pricing, and launch plans

  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Adrenocortical Carcinoma therapeutics in each of the markets covered

  • Understand the magnitude of Adrenocortical Carcinoma population by its epidemiology

  • The Adrenocortical Carcinoma Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

 

Table of Contents

  1. Key Insights 

  2. Executive Summary of Adrenocortical Carcinoma

  3. Adrenocortical Carcinoma Disease Background and Overview

  • Adrenocortical Carcinoma Sign and Symptoms

  • Adrenocortical Carcinoma Pathophysiology

  • Adrenocortical Carcinoma Risk Factors

  • Adrenocortical Carcinoma Diagnosis

  1. Adrenocortical Carcinoma Patient Journey

  2. Adrenocortical Carcinoma Epidemiology and Patient Population

  3. Adrenocortical Carcinoma Treatment Algorithm, Current Treatment, and Medical Practices

  4. KOL Views on Adrenocortical Carcinoma 

  5. Adrenocortical Carcinoma Unmet Needs

  6. Appendix

  7. DelveInsight Capabilities

  8. Disclaimer

*The table of contents is not exhaustive; will be provided in the final report

 

About  DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

 

Related Reports-

Adrenocortical Carcinoma Market Insight, Epidemiology and Market Forecast 2030
DelveInsight’ s Adrenocortical Carcinoma Market Insights, Epidemiology and Market Forecast 2030 report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology.

 

Adrenocortical Carcinoma Pipeline Insights, 2020
Adrenocortical Carcinoma Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Adrenocortical Carcinoma market.

 

 

 

 

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/haridwartoday/gurgaon-samachar.com/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share

Categories